High-dose simvastatin exhibits enhanced lipid-lowering effects relative to simvastatin/ezetimibe combination therapy

Circulation: Cardiovascular Genetics

Volumn 7, Issue 6, 2014, Pages 955-964

  Snowden, Stuart G ^a   Grapov, Dmitry ^b,c   Settergren, Magnus ^d   D'Alexandri, Fabio Luiz ^a   Haeggström, Jesper Z ^a   Fiehn, Oliver ^b   Hyötyläinen, Tuulia ^e,f   Pedersen, Theresa L ^c   Newman, John W ^b,c   Orešič, Matej ^e,f   Pernow, John ^d   Wheelock, Craig E ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c U S DEPARTMENT OF AGRICULTURE   (United States)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

^f STENO DIABETES CENTER   (Denmark)

Author keywords

Eicosanoids; Ezetimibe; Hydroxymethylglutaryl CoA reductase inhibitors; Lipids; Mass spectrometry; Simvastatin

Indexed keywords

C REACTIVE PROTEIN; CERAMIDE; ENDOCANNABINOID; EZETIMIBE PLUS SIMVASTATIN; ICOSANOID; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYSOPHOSPHATIDYLCHOLINE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; SIMVASTATIN; SPHINGOMYELIN; TRIACYLGLYCEROL; AZETIDINE DERIVATIVE; CHOLESTEROL; DRUG COMBINATION; HYPOCHOLESTEROLEMIC AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; DRUG MEGADOSE; DYSGLYCEMIA; FEMALE; HUMAN; LIPID BLOOD LEVEL; LIPID COMPOSITION; LIQUID CHROMATOGRAPHY; MALE; MONOTHERAPY; PLEIOTROPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; TANDEM MASS SPECTROMETRY; TREATMENT DURATION; ANALYSIS OF VARIANCE; BLOOD; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG COMBINATION; HYPERCHOLESTEROLEMIA; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; ANALYSIS OF VARIANCE; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CERAMIDES; CHOLESTEROL; CHOLESTEROL, LDL; DISCRIMINANT ANALYSIS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; EZETIMIBE, SIMVASTATIN DRUG COMBINATION; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PHOSPHATIDYLCHOLINES; SIMVASTATIN; SPHINGOMYELINS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84925863928     PISSN: 1942325X     EISSN: 19423268     Source Type: Journal    
DOI: 10.1161/CIRCGENETICS.114.000606     Document Type: Article

References (50)

1. Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012;307:1302-1309
2. Robinson JG, Wang S, Smith BJ, Jacobson TA. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol. 2009;53:316-322
3. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al; CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebocontrolled trial. Lancet. 2004;364:685-696
4. Haffner SM. Management of dyslipidemia in adults with diabetes. Diabetes Care. 1998;21:160-178
5. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al; European Society of Cardiology (ESC) Committee for Practice Guidelines (CPG). European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2007;28:2375-2414
6. Ornish D, Scherwitz LW, Billings JH, Brown SE, Gould KL, Merritt TA, et al. Intensive lifestyle changes for reversal of coronary heart disease. JAMA. 1998;280:2001-2007
7. Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterollowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005-2016
8. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380:565-571
9. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med. 1988;319:24-33
10. Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A. 2005;102:8132-8137
11. Dujovne CA, Ettinger MP, McNeer JF, Lipka LJ, LeBeaut AP, Suresh R, et al; Ezetimibe Study Group. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol. 2002;90:1092-1097
12. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al; ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358:1431-1443
13. Gotto AM Jr, Farmer JA. Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol. Nat Clin Pract Cardiovasc Med. 2006;3:664-672
14. Rotella CM, Zaninelli A, Le Grazie C, Hanson ME, Gensini GF. Ezetimibe/ simvastatin vs simvastatin in coronary heart disease patients with or without diabetes. Lipids Health Dis. 2010;9:80
15. Blum A, Shamburek R. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis. 2009;203:325-330
16. Palinsk W. New evidence for beneficial effects of statins unrelated to lipid lowering. Arterioscler Thromb Vasc Biol. 2001;21:3-5
17. Jones PH. Statins as the cornerstone of drug therapy for dyslipidemia: monotherapy and combination therapy options. Am Heart J. 2004;148(1 suppl):S9-S13
18. Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, LeBeaut AP, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002;40:2125-2134
19. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 suppl 2):S1-S45
20. Settergren M, Böhm F, Rydén L, Pernow J. Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease. Eur Heart J. 2008;29:1753-1760
21. Grapov D, Adams SH, Pedersen TL, Garvey WT, Newman JW. Type 2 diabetes associated changes in the plasma non-esterified fatty acids, oxylipins and endocannabinoids. PLoS One. 2012;7:e48852
22. Nygren H, Seppänen-Laakso T, Castillo S, Hyötyläinen T, Oreši M. Liquid chromatography-mass spectrometry (LC-MS)-based lipidomics for studies of body fluids and tissues. Methods Mol Biol. 2011;708:247-257
23. Benjamini Y, Hochberg Y. Controlling the false discovery rate-a practical and powerful approach to multiple testing. J Roy Stat Soc B Met. 1995;57:289-300
24. Dabney A, Storey JD. qvalue: Q-value estimation for false discovery rate control. R package version 1.36.0; 2013
25. Wheelock ÅM, Wheelock CE. Trials and tribulations of 'omics data analysis: assessing quality of SIMCA-based multivariate models using examples from pulmonary medicine. Mol Biosyst. 2013;9:2589-2596
26. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498-2504
27. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al; JUPITER Trial Study Group. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373:1175-1182
28. Bergheanu SC, Reijmers T, Zwinderman AH, Bobeldijk I, Ramaker R, Liem AH, et al. Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: investigating differential effects among statins. Curr Med Res Opin. 2008;24:2477-2487
29. Kaddurah-Daouk R, Baillie RA, Zhu H, Zeng ZB, Wiest MM, Nguyen UT, et al. Lipidomic analysis of variation in response to simvastatin in the Cholesterol and Pharmacogenetics Study. Metabolomics. 2010;6:191-201
30. Birnbaum Y, Ye Y. Pleiotropic effects of statins: the role of eicosanoid production. Curr Atheroscler Rep. 2012;14:135-139
31. Zhou G, Ge S, Liu D, Xu G, Zhang R, Yin Q, et al. Atorvastatin reduces plaque vulnerability in an atherosclerotic rabbit model by altering the 5-lipoxygenase pathway. Cardiology. 2010;115:221-228
32. Shearer GC, Newman JW. Impact of circulating esterified eicosanoids and other oxylipins on endothelial function. Curr Atheroscler Rep. 2009;11:403-410
33. Shearer GC, Newman JW. Lipoprotein lipase releases esterified oxylipins from very low-density lipoproteins. Prostaglandins Leukot Essent Fatty Acids. 2008;79:215-222
34. Simon JA, Lin F, Hulley SB, Blanche PJ, Waters D, Shiboski S, et al. Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study. Am J Cardiol. 2006;97:843-850
35. Ozerova IN, Paramonova IV, Olfer'ev AM, Akhmedzhanov NM, Aleksandrova MA, Perova NV. Effects of simvastatin on the phospholipid composition of high-density lipoproteins in patients with hypercholesterolemia. Bull Exp Biol Med. 2001;132:763-765
36. Yanagita T, Yamamoto K, Ishida S, Sonda K, Morito F, Saku K, et al. Effects of simvastatin, a cholesterol synthesis inhibitor, on phosphatidylcholine synthesis in HepG2 cells. Clin Ther. 1994;16:200-208
37. Jiang XC, Paultre F, Pearson TA, Reed RG, Francis CK, Lin M, et al. Plasma sphingomyelin level as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol. 2000;20:2614-2618
38. Schlitt A, Blankenberg S, Yan D, von Gizycki H, Buerke M, Werdan K, et al. Further evaluation of plasma sphingomyelin levels as a risk factor for coronary artery disease. Nutr Metab (Lond). 2006;3:5
39. Yeboah J, McNamara C, Jiang XC, Tabas I, Herrington DM, Burke GL, et al. Association of plasma sphingomyelin levels and incident coronary heart disease events in an adult population: Multi-Ethnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol. 2010;30:628-633
40. Stübiger G, Aldover-Macasaet E, Bicker W, Sobal G, Willfort-Ehringer A, Pock K, et al. Targeted profiling of atherogenic phospholipids in human plasma and lipoproteins of hyperlipidemic patients using MALDI-QITTOF-MS/MS. Atherosclerosis. 2012;224:177-186
41. Peter Slotte J. Lateral domain heterogeneity in cholesterol/phosphatidylcholine monolayers as a function of cholesterol concentration and phosphatidylcholine acyl chain length. Biochim Biophys Acta. 1995;1238:118-126
42. Strauss V, Mellert W, Wiemer J, Leibold E, Kamp H, Walk T, et al. Increased toxicity when fibrates and statins are administered in combination-a metabolomics approach with rats. Toxicol Lett. 2012;211:187-200
43. Epps KC, Wilensky RL. Lp-PLA-a novel risk factor for high-risk coronary and carotid artery disease. J Intern Med. 2011;269:94-106
44. Schmitz G, Ruebsaamen K. Metabolism and atherogenic disease association of lysophosphatidylcholine. Atherosclerosis. 2010;208:10-18
45. Wilensky RL, Shi Y, Mohler ER III, Hamamdzic D, Burgert ME, Li J, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med. 2008;14:1059-1066
46. Herrmann J, Mannheim D, Wohlert C, Versari D, Meyer FB, McConnell JP, et al. Expression of lipoprotein-associated phospholipase A(2) in carotid artery plaques predicts long-term cardiac outcome. Eur Heart J. 2009;30:2930-2938
47. Gonçalves I, Edsfeldt A, Ko NY, Grufman H, Berg K, Björkbacka H, et al. Evidence supporting a key role of Lp-PLA2-generated lysophosphatidylcholine in human atherosclerotic plaque inflammation. Arterioscler Thromb Vasc Biol. 2012;32:1505-1512
48. Verschuren L, Radonjic M, Wielinga PY, Kelder T, Kooistra T, van Ommen B, et al. Systems biology analysis unravels the complementary action of combined rosuvastatin and ezetimibe therapy. Pharmacogenet Genomics. 2012;22:837-845
49. Trupp M, Zhu H, Wikoff WR, Baillie RA, Zeng ZB, Karp PD, et al. Metabolomics reveals amino acids contribute to variation in response to simvastatin treatment. PLoS One. 2012;7:e38386
50. Ooga T, Sato H, Nagashima A, Sasaki K, Tomita M, Soga T, et al. Metabolomic anatomy of an animal model revealing homeostatic imbalances in dyslipidaemia. Mol Biosyst. 2011;7:1217-1223.